USP and Public Policy

usp public policy
Left
usp public policy

Refine Your Search

All Results
USP Global Public Policy Position: Identifying and addressing vulnerabilities in the upstream medicines supply chain to build resilience and reduce drug shortages (2024)
Identifying and addressing vulnerabilities in the upstream pharmaceutical supply chain are essential to mitigating and preventing drug shortages and to ensuring patients have access to the critical… Learn More
USP Comments on the Senate Finance Committee’s Legislative Draft "Drug Shortage Prevention and Mitigation Act” (2024)
Learn More
USP Statement for the Record: Submitted to the Senate Finance Committee for the Hearing: “Drug Shortages: Examining Supply Challenges, Impacts, and Policy Solutions from a Federal Health Program Perspective” (2023)
United States Pharmacopeia (USP) Statement for the Record Submitted to the Senate Finance Committee for the Hearing: “Drug Shortages: Examining Supply Challenges, Impacts, and Policy Solutions from a… Learn More
USP Statement for the Record: Submitted to Ways and Means Hearing on Examining Chronic Drug Shortages in the United States (2024)
United States Pharmacopeia (USP) Statement for the Record, submitted to the House Committee on Ways and Means Hearing on Examining Chronic Drug Shortages in the United States. Submitted 2/12/2024. Learn More
USP Statement for the Record: For the Hearing Drug Shortage Health and National Security Risks- Underlying Causes and Needed Reforms (2023)
United States Pharmacopeia (USP) is pleased to submit the following statement for the record on the hearing “Drug Shortage Health and National Security Risks: Underlying Causes and Needed Reforms Learn More
USP Comment Letter: Submitted to the Senate Finance Committee's Request for Information on Drug Shortages (2023)
USP is pleased to provide a response to the bicameral Request for Information (RFI) on the increase in drug shortages. Submitted July 7, 2023. Learn More

Document Classification

Topics